UNM Bounces Back — But the Debate Hinges on Disability Claims

UNM heads into today's Q2 print having recovered some ground, with the stock up 1.7% on Tuesday to $87.93 — clawing back part of a 2.4% monthly slide.

Options traders are not showing much anxiety heading into the release. The put/call ratio is running at just 0.055, fractionally below its 20-day average of 0.062, and close to the 52-week low of 0.040. That near-absence of hedging demand points to a market that is either relaxed about the outcome or simply not active in the options market for this name. Short interest reinforces that calm: bears hold just 1.8% of the free float, a level that has drifted roughly 10% lower over the past month. Borrow availability is vast — over 6,000% of short interest — meaning shares to borrow are essentially unconstrained. There is no short-side pressure here.

The real tension heading into the print is fundamental, not technical. Analysts have been lifting targets with notable consistency — JP Morgan, Jefferies, Evercore ISI, and Barclays all raised over the past three weeks, pushing the consensus mean to $102, which implies about 16% upside from the current price. The bull case is structural: a group benefits franchise generating more than 20% return on equity, 90%-plus free cash flow conversion, and a tailwind from higher reinvestment yields. Bears counter with a specific number — group disability benefit ratios projected at 62–63%, signalling claims costs that are running faster than premium growth. That tension between a strong franchise and rising disability incidence is the crux of what the Q2 numbers will either resolve or deepen. Morgan Stanley, sitting at Equal-Weight with an $87 target, effectively marks the floor of Street conviction — right at current levels.

Among peers, MET gained 2.4% on the week and SPNT added nearly 4%, suggesting the broader insurance group has found buyers. GL fell 5.4% over the same period, a divergence that highlights how claims-sensitive names are being treated differently even within the sector.

The Q2 report will test whether Unum's disability benefit ratios are stabilising, or whether the claims pressure flagged in earlier guidance is proving stickier than the bullish target-raise cycle anticipated.